Susquehanna International Group, LLP Inhibrx, Inc. Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2024

A detailed history of Susquehanna International Group, LLP transactions in Inhibrx, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 63,710 shares of INBX stock, worth $902,770. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,710

Previous 106,195 40.01%

Holding current value

$902,770

Previous $4.04 Million 44.81%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$32.76 - $39.56 $1.39 Million - $1.68 Million	-42,485 Reduced 40.01%	63,710 $2.23 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $1.12 Million - $2.94 Million	77,242 Added 266.78%	106,195 $4.04 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $52,038 - $86,928	3,304 Added 12.88%	28,953 $531,000
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $771,459 - $1.27 Million	-45,487 Reduced 63.94%	25,649 $665,000
Q1 2023 May 16, 2023	BUY	$18.45 - $27.14 $1.02 Million - $1.5 Million	55,262 Added 348.13%	71,136 $1.34 Million

Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $587,096 - $969,669	-29,093 Reduced 64.7%	15,874 $391,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $159,919 - $341,521	13,810 Added 44.32%	44,967 $807,000
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $8,451 - $25,057	-992 Reduced 3.09%	31,157 $354,000
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $251,548 - $546,097	-12,647 Reduced 28.23%	32,149 $716,000
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $1.2 Million - $2.06 Million	44,796 New	44,796 $1.96 Million

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Inhibrx, Inc. Transaction History